International: +1-347-960-6455
Acquired Immunodeficiency Syndrome (AIDS) Related Cancer Therapeutics - Pipeline Analysis 2018

Acquired Immunodeficiency Syndrome (AIDS) Related Cancer Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10110 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Oncology
Select License Type
$2200
$2600
$3950

Acquired immunodeficiency syndrome (AIDS) related cancer include those types of cancer which occurs in patients suffering from AIDS. People with AIDS are reported to be highly suspected to the occurrence of lymphomas. According to the American Society of Clinical Oncology, Kaposi sarcoma is very common in patients with AIDS; whereas non-Hodgkin’s lymphoma is second most common in patients with AIDS. Women with AIDS are at high risk for developing cervical intraepithelial neoplasia. The National Cancer Institute is in the process of developing chemotherapy and HAART; and EPOCH-rituximab, for the treatment of AIDS related lymphoma.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.